The platelet-rich plasma lysate use in the treatment of persistent epithelial defects after keratoplasty
- Authors: Shakhbazyan N.P.1, Trufanov S.V.2, Subbot A.M.1
-
Affiliations:
- Research Institute of Eye Diseases
- Pavlov First St. Petersburg State Medical University
- Issue: Vol 14, No 2 (2021)
- Pages: 27-35
- Section: Original researches
- URL: https://journals.rcsi.science/ov/article/view/62857
- DOI: https://doi.org/10.17816/OV62857
- ID: 62857
Cite item
Abstract
AIM: to evaluate the effectiveness of the platelet-rich plasma lysate (PRP lysate) use in the treatment of persistent epithelial defects (PED) after keratoplasty.
MATERIALS AND METHODS: In the study, 60 patients with PED after keratoplasty were included. The 1st group (24 cases) included patients after keratoplasty with “low risk” of rejection, and the 2nd group – 36 cases after keratoplasty with “high risk” of rejection. Each group was divided into two subgroups – control subgroups 1a (cases 10) and 2a (cases 16), where patients received only standard postoperative therapy, and the main subgroups 1b (cases 14) and 2b (cases 20), in which PRP lysate was prescribed against the background of standard therapy, starting from the Day 15 post-op. As the criterion for effective treatment, complete persistent epithelialization after keratoplasty was considered.
RESULTS: The effectiveness of the use of PRP lysate in the subgroup 1b was 85.7%, while complete epithelialization in the control subgroup 1a was recorded in 70%; in the subgroup 2b, complete epithelialization was observed in 55%, in the control subgroup 2a – in 43.75%.
CONCLUSION: The use of PRP lysate in the treatment of PED after corneal transplantation as an adjuvant therapy is effective and safe in both high and low risk keratoplasty. In the examined category of patients, treatment with blood derivatives increases the frequency and rate of complete epithelialization.
Full Text
##article.viewOnOriginalSite##About the authors
Nare P. Shakhbazyan
Research Institute of Eye Diseases
Author for correspondence.
Email: nare_shakhbazyan@mail.ru
ORCID iD: 0000-0002-1857-6425
postgraduate student
Russian Federation, 11A, Roccolimo str., Moscow, 119021Sergey V. Trufanov
Pavlov First St. Petersburg State Medical University
Email: trufanov05@mail.ru
ORCID iD: 0000-0003-4360-793X
MD, Dr. Sci. (Med.)
Russian Federation, 6–8 L’va Tolstogo str., Saint Petersburg, 197022Anastasia M. Subbot
Research Institute of Eye Diseases
Email: kletkagb@gmail.com
ORCID iD: 0000-0002-8258-6011
PhD, Cand. Sci. (Med.)
Russian Federation, 11A, Roccolimo str., Moscow, 119021References
- Lynch MD, Bashir S. Applications of platelet-rich plasma in dermatology: A critical appraisal of the literature. Journal of Dermatological Treatment. 2016;27(3):285–289. doi: 10.3109/09546634.2015.1094178
- Andia E, Rubio-Azpeitia J, Martin JI, Abate M. Current concepts and translational uses of platelet rich plasma biotechno-logy. Biotechnology, Deniz Ekinci, IntechOpen. 2015. doi: 10.5772/59954
- Sommeling CE, Heyneman A, Hoeksema H, et al. The use of platelet-rich plasma in plastic surgery: a systematic review. J Plast Reconstr Aesthet Surg. 2013;66(3):301–311. doi: 10.1016/j.bjps.2012.11.009
- Mazzucco L, Balbo V, Cattana E, et al. Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet, Regen PRP-kit, Plateltex and one manual procedure. Vox Sang. 2009;97(2):110–118. doi: 10.1111/j.1423-0410.2009.01188. x
- Le G, Kaux JF, Seidel L, et al. Étude comparative de cinq techniques de préparation plaquettaire (platelet-rich plasma). Pathol Biol. (Paris). 2011;59(3):157–160. (In French.) doi: 10.1016/j.patbio.2009.04.007
- Castillo TN, Pouliot MA, Kim HJ, Dragoo JL. Comparison of growth factor and platelet concentration from commercial platelet-rich plasma separation systems. Am J Sports Med. 2010;39(2): 266–271. doi: 10.1177/0363546510387517
- Wasterlain AS, Braun HJ, Dragoo JL. Contents and formulations of platelet rich plasma. Platelet Rich Plasma in Musculoskeletal Practice. London; 2016. P. 1–29.
- Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus Med Hemother. 2013;40(5):326–335. doi: 10.1159/000354061
- Anitua E, Sanchez M, Merayo-Lloves J, et al. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF induced myodifferentiation. Investigative ophthalmology visual science. 2011;52(9):6066–6073. doi: 10.1167/iovs.11-7302
- Abu-Ameerh MA, Jafar HD, Hasan MH, et al. Platelet lysate promotes re-epithelialization of persistent epithelial defects a pilot study. Int Ophthalmology. 2019;39(7):1483–1490. doi: 10.1007/s10792-018-0968-1
- Santos S, Sigurjonsson ÓE, Custódio CA, Mano J. Blood Plasma Derivatives for Tissue Engineering and Regenerative Medicine Therapies. Tissue Eng Part B Rev. 2018;24(6):454–462. doi: 10.1089/ten.TEB.2018.0008
- Amable PR, Carias RB, Teixeira MV, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67. doi: 10.1186/scrt218
- Drago L, Bortolin M, Vassena C, et al. Antimicrobial activity of pure platelet-rich plasma against microorganisms isolated from oral cavity. BMC Microbiol. 2013;13:47. doi: 10.1186/1471-2180-13-47
- Del Fabbro M, Ceresoli V, Lolato A, Taschieri S. Effect of platelet concentrate on quality of life after periradicular surgery: a randomized clinical study. J Endod. 2012;38(6):733–739. doi: 10.1016/j.joen.2012.02.022
- van Osch GJ, Bernsen MR, van Buul GM, et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med. 2011;39(11):2362–2370. doi: 10.1177/036354651141927
- Mazzocca AD, McCarthy BR, Intravia J, et al. An in vitro evaluation of the anti-inflammatory effects of platelet-rich plasma, ketorolac, and methylprednisolone. Arthroscopy. 2013;29(4):675–683. doi: 10.1016/j.arthro.2012.12.005
- Peerbooms JC, Sluimer J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in lateral epicondylitis in a double-blind randomized controlled trial: Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med. 2010;38(2):255–262. doi: 10.1177/0363546509355445
- Deikalo VP, Mastykov AN, Boloboshko KB. Obogashhennaja trombocitami plazma v lechenii zabolevanij i povrezhdenij oporno-dvigatel’nogo apparata. Vestnik VGMU. 2011;10(4):6–12. (In Russ.)
- Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489–496. doi: 10.1016/j.joms.2003.12.003
- Huang CJ, Sun YC, Christopher K, et al. Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives. PloS one. 2018;12(2): e0171008. doi: 10.1371/journal.pone.0171008
- McCulley JP, Horowitz B, Husseini ZM, Horowitz M. Topical fibronectin therapy of persistent corneal epithelial defects. Fibronectin Study Group. Trans Am Ophthalmol Soc. 1993;91:367–386.
- Fu Y, Liu J, Tseng SC. Ocular surface deficits contributing to persistent epithelial defect after penetrating keratoplasty. Cornea. 2012;31(7):723–729. doi: 10.1097/ICO.0b013e31821142ee
- Loshkareva AO. Terapija hronicheskih narushenij jepitelizacii rogovicy gerpesvirusnoj jetiologii s ispol’zovaniem autologichnoj bogatoj trombocitami plazmy [dissertation]. Moscow; 2018. (In Russ.) Available from: https://www.dissercat.com/content/terapiya-khronicheskikh-narushenii-epitelizatsii-rogovitsy-gerpesvirusnoi-etiologii-s-ispolz
- Borovkova NV, Filatova IA, Chentsova EV, et al. Efficacy of platelet-rich plasma lysate in patients with corneal erosion or post-traumatic scarring of the tissues of the eyelids. Russian Ophthalmological Journal. 2020;13(3):8–14. (In Russ.) doi: 10.21516/2072-0076-2020-13-3-8-14.
- Rumelt S, Bersudsky V, Blum-Hareuveni T, Rehany U. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002;21(8):759–765. doi: 10.1097/00003226-200211000-00005
- Rumelt S, Bersudsky V, Blum-Hareuveni T, et al. Preexisting and postoperative glaucoma in repeated corneal transplantation. Cornea. 2002;21(8):759–765. doi: 10.1097/00003226-200211000-00005
- Puchkovskaja NA. Lechebnaja keratoplastika i vozmozhnosti stimuljacii regenerativnoj sposobnosti rogovoj obolochki. Oftal’mologichcheskij zhurnal. 1983;2:69–71. (In Russ.)
- Katzman LR, Jeng BH. Management strategies for persistent epithelial defects of the cornea. Saudi J Ophthalmol. 2014;28(3): 168–172. doi: 10.1016/j.sjopt.2014.06.011
- Hos D, Matthaei M, Bock F, et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. Prog Retin Eye Res. 2019;73:100768. doi: 10.1016/j.preteyeres.2019.07.001
- Trufanov SV, Subbot AM, Malozhen SA, et al. Risk factors, clinical presentations, prevention, and treatment of corneal graft rejection. Vestnik oftal’mologii. 2016;132(6):108–116. (In Russ.) doi: 10.17116/oftalma20161326108-116